Articles tagged with Cancer Patients
A study published in the Journal for ImmunoTherapy of Cancer found that immunotherapy outcomes differ based on dosing strategy and patient weight. Overweight patients receiving weight-based dosing lived an average of over 20 months, compared to less than 10 months for lighter patients.
A study found that nearly half of patients with gynecologic cancer experience financial toxicity, which can lead to worsening health outcomes. Younger patients are at a higher risk due to limited financial safety nets and ability to work.
Researchers found that pralsetinib achieved an overall response rate of 70% and complete response rate of 11% in patients with no prior systemic treatment for advanced RET fusion-positive NSCLC. In the thyroid arm, the ORR was 71% in patients with treatment-naïve RET-mutant medullary thyroid cancer.
A large study found that COVID-19 vaccines induce a strong immune response in patients with various types of cancer, with high seroconversion rates among solid tumor patients. However, those receiving treatments for blood cancers had lower but still significant rates, highlighting the importance of vaccination in vulnerable populations.
Research shows that hospitalized individuals with active cancer are more likely to die from COVID-19 than those with a history of cancer or no cancer diagnosis. Patients with blood-related cancers face the greatest risk of death, while recent cancer therapy is not linked to worse outcomes.
A recent study found that fewer than one in three women aged 64 to 66 met the criteria to discontinue cervical cancer screening. The majority of women in this age group may be at risk for cervical cancer due to inadequate screening or preexisting high-risk conditions.
A £8 million project led by the University of Warwick aims to develop new technology combining probes that detect cancer tumours through the skin with high-precision robotic surgery. The Terabotics project has the potential to lead to real-time diagnosis and more comprehensive removal of tumours with reduced need for follow-up surgery.
Researchers at Mayo Clinic Cancer Center found that remote patient monitoring reduced the risk of hospitalization for cancer patients with COVID-19 by 78%. The program used in-home technology to monitor oxygen levels and vital signs, resulting in fewer hospitalizations and ICU admissions.
The Phase II study showed that sotorasib achieved a 37.1% objective response rate and 12.5 months median overall survival in previously treated patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC). The drug was found to be safe and tolerable, with manageable toxicities.
Researchers at the University of Turku discovered a novel antibody treatment that reactivates the immune defense system in patients with advanced-stage cancer. The treatment activates killer T cells and lowers the suppressive potential of macrophages, leading to increased inflammation and white blood cell activity.
Researchers found that nivolumab significantly reduced bladder cancer recurrence after surgery in high-risk patients. Disease-free survival was 21 months for nivolumab recipients compared to 10.9 months for placebo recipients.
A national survey of breast cancer patients and oncologists reveals that nearly three-quarters of patients use complementary medicine during treatment, yet doctors often fail to discuss integrative health with patients. Patients report finding hope and improving quality of life through these therapies.
The study found that rivaroxaban is safe for patients with luminal gastrointestinal cancer, while apixaban should be used cautiously due to higher bleeding risk. DOACs can also be used in non-luminal GI cancers like pancreatic and hepatobiliary cancers.
Researchers found that aging decreases T-cell survival and function, while ceramide signaling weakens anti-tumor T-cells. Blocking certain ceramide molecules improves the anti-tumor function of aging T-cells.
A biomarker based on circulating tumour DNA (ctDNA) can predict the likelihood of bowel cancer recurrence after surgery and chemotherapy. The test measures ctDNA levels before and after treatment to provide real-time information on chemotherapy effectiveness.
Researchers at UNIGE create 3D spheroidal tumor models incorporating tumor cells and patient-specific immune cells to test treatment efficacy. This innovative approach enables personalized treatment options, potentially reducing reliance on animal experiments.
A new study published in PLOS ONE demonstrates the potential of machine learning to identify high-risk patients with pancreatic cancer up to 2 years before diagnosis. The algorithm achieved high sensitivity and specificity rates, identifying 41% of patients under 60 as high risk and 72% of those diagnosed as having a detectable risk. T...
Researchers at Huntsman Cancer Institute have identified a specific gene-regulating protein complex to target in the treatment of synovial sarcoma. The study provides new understanding of how the disease develops and spreads, offering potential breakthroughs in diagnosis and therapy.
A phase 3 clinical trial shows that immunotherapy nivolumab after surgery can nearly double the time before relapse for patients with high-risk urothelial cancer. The treatment significantly reduces metastatic recurrence risk, offering hope for thousands of patients worldwide.
The La Jolla Institute for Immunology has launched the Cancer Epitope Database and Analysis Resource (CEDAR), a new global cancer immunology resource, thanks to $4.2 million in National Cancer Institute funding. Researchers can now easily search and contribute data on potential immune system targets on various types of cancer cells.
A study found that cancer patients had lower SARS-CoV-2 antibody levels compared to healthcare workers. Health care workers in Japan had higher SARS-CoV-2 antibody levels, indicating a possible immune response to the virus.
Haizhen Wang, a MUSC Hollings Cancer Center researcher, has received a $225,000 Young Investigator grant from the Melanoma Research Alliance. She will investigate the function of protein CDK6 in T-cells to improve melanoma therapy outcomes.
A new study found that delaying lung cancer surgery for more than 12 weeks after diagnosis is associated with a higher risk of recurrence and death. Patients who underwent surgery within this time frame lived 7.5 months longer than those who delayed treatment.
Even among insured individuals, up to 10% of cancer survivors delayed follow-up care due to financial constraints. Financial stress and anxiety hinder timely survivorship care, particularly among vulnerable populations such as racial minorities, women, and those with lower incomes.
A new Penn Medicine study shows that blood cancer patients with lower antibody levels can rely on T cells to combat COVID-19. The research found that patients with higher CD8 T cell counts were more than three times likelier to survive than those with lower counts.
A new imaging technique using fluorothymidine (FLT) is being tested to predict the success of bone marrow transplants. The trial aims to reduce waiting time for patients and improve survival rates, currently 30% over three years after failure.
The National Foundation for Cancer Research has announced the winners of its 2021 Salisbury Award Competition, recognizing promising cancer research innovations. The first prize winner is TanoMed's technology training host immunity against a specific member of the carcinoembryonic antigen-related cell adhesion molecule family, CEACAM5.
Researchers developed an AI system to guide oncologists in treating head and neck cancer patients, considering treatment efficacy and potential future decisions. The system analyzes real patient data to provide personalized recommendations and maximize survival outcomes while minimizing chemotherapy and radiation side effects.
New research suggests that anti-cancer therapies can hasten cellular aging, leading to increased inflammation and fatigue in patients with head and neck cancer. Epigenetic changes associated with these treatments may contribute to age-related conditions.
The USC Norris Comprehensive Cancer Center has formed partnerships with the Lazarex Cancer Foundation to create Cancer Wellness HUBs in Los Angeles, addressing health disparities through community engagement and education. The initiative aims to provide vital resources and support services for cancer patients and their families.
A dental school researcher has received FDA approval to begin clinical trials for a new cancer therapy using a protein found in an oral bacterium. The treatment, Leukothera, rapidly kills cancer cells without compromising the immune system, offering a potential alternative to existing treatments.
The University of Pennsylvania School of Medicine has doubled the percentage of Black participants in cancer clinical trials through community outreach and engagement efforts. The initiative improved access and treatment for historically underrepresented groups, with significant increases observed in non-therapeutic interventional and ...
The GEM ExTra test uses whole exome sequencing and RNA sequencing to detect actionable mutations in patients with advanced solid tumors. It has been validated through clinical utilization and provides clinically actionable information to guide patient management decisions.
In a Phase I trial, IACS-6274 demonstrated successful target inhibition and early signs of anti-tumor activity in 60% of evaluable patients. Durable disease stabilization was observed in six patients with biomarker-defined advanced cancers.
A new study published in the Journal of Clinical Oncology reports findings on Huntsman at Home, a cancer hospital-at-home model that demonstrates lower costs and better outcomes for patients. The study found that participants had 55% fewer hospitalizations and 47% lower healthcare costs compared to those who did not participate.
A lack of insurance leads to worse cancer survival across the 16 most common cancers, with uninsured patients 60-64 facing significantly poorer outcomes than their older counterparts. This disparity is driven by the high costs of newer potentially lifesaving treatments, which can be unaffordable for those without insurance.
A study published in the European Journal of Preventive Cardiology found that nearly one in four heart failure patients experience depression or anxiety, compared to 23% of breast cancer patients, 22% of prostate cancer patients, and 15% of digestive organ cancer patients. Heart failure patients are also at a higher risk of developing ...
A study by Kaiser Permanente found that insured patients with cancer had better survival rates, especially among Black and Latino patients. The researchers analyzed data from the California Cancer Registry and found lower mortality rates among Kaiser Permanente members in Southern California.
A new study examines the safety of COVID-19 vaccines in patients with cancer, providing insights into potential risks and benefits. The research found that while some cancer treatments may interact with COVID-19 vaccines, the overall risk is low.
Researchers at Huntsman Cancer Institute discovered that nicotinamide phosphoribosyltransferase (NAMPT) plays a key role in how immune cells fight melanoma tumors. The study found that disrupting the NAMPT pathway impairs antitumor function, and novel therapies targeting this pathway may lead to improved outcomes for patients.
A phase II study by Penn Medicine shows rucaparib helped control cancer growth in patients with BRCA or PALB2 genetic mutations. The results support the use of rucaparib as a maintenance therapy for pancreatic cancer patients, offering a safe and effective alternative to chemotherapy.
A new study found that individuals experiencing pre-loss grief symptoms can adjust, but certain factors such as gender and caregiving burden exacerbate the experience. The research documented a significant correlation between dementia patients' family members and severe pre-loss grief.
A new UCSF study reports that cancer patients experience a deep sense of loneliness during the COVID-19 pandemic, with 53% of participants classified as lonely. The study also found higher levels of depression, fatigue, and sleep disturbance among lonely patients.
Researchers screened over 60,000 blood samples from asymptomatic individuals for IgG antibody to the viral spike protein, finding strong correlations between high anti-S IgG levels and neutralizing activity. The study also showed age-related differences in antibody responses and a higher prevalence of COVID-19 among African Americans.
Researchers developed an AI system, TOAD, that accurately predicts the origin of tumors in cancer cases with unknown primary sites. The model, trained on gigapixel pathology images, correctly identified cancer types and listed diagnoses as top predictions 96% of the time.
A new study aims to evaluate the effectiveness of an automated, smartphone-based approach to incentivizing smoking cessation among low-income adults in Oklahoma. The 5-year project will enroll 532 participants and assess the impact of monetary incentives on smoking abstinence.
A computational method using machine learning and feature sets derived from molecular simulation can predict the functional consequences of genetic variation in cancer drugs. This technology has the potential to accurately diagnose cancer variants and improve treatment outcomes by tailoring therapy to individual genetic profiles.
A study at ESMO Breast Cancer 2021 Virtual Congress reveals breast cancer survivors experience varying levels of symptoms after treatment, with some requiring active symptom management. Patients with comorbidities, such as heart disease and diabetes, are more likely to experience a high symptom burden.
A team of researchers, including Saket Navlakha and Dr. Sejal Morjaria, developed a computational tool to predict COVID-19 severity in cancer patients. The tool has an accuracy rate of 70-85% and prevents unnecessary expensive testing, improving patient care.
New research reveals patients with multiple comorbidities are more likely to be screened for colorectal cancer than those without any health conditions. Regular screenings significantly reduce cancer mortality.
A new set of guidelines developed by AATS and ESTS recommends a 30-day course of Venous Thromboembolism (VTE) prophylaxis post-discharge for patients undergoing surgical resection for lung or esophagus cancer. The guideline panel endorsed by American Society of Hematology and International Society on Thrombosis and Haemostasis found th...
A new test, called Guardant Reveal, can detect residual cancer DNA in the blood of patients after treatment without knowing the specific mutations present in their tumor. The study found that this approach was similar in sensitivity and specificity to traditional methods.
Breast cancer patients experience frequent job changes after diagnosis, with around ten percent reporting involuntary changes. The study suggests that a supportive work environment and understanding from managers can facilitate a satisfactory return to work.
A new study from the University of Missouri School of Medicine found that people of color, those with a higher income, and younger individuals are more likely to participate in cancer clinical trials. The analysis of 20,053 respondents showed an average overall clinical trial participation rate of 6.51%, with significant differences in...
A recent study found that only 16% of male teenagers received the HPV vaccine, highlighting a significant gap in vaccination rates. The vaccine is essential for preventing oropharyngeal cancer, which affects 80% of male patients diagnosed with this condition.
A recent study by the University of Eastern Finland found that middle-aged men who experience loneliness are at an increased risk of developing cancer. The study, which followed 2,570 men over time, found that loneliness was associated with a 10% higher risk of cancer.
A multi-institutional team of researchers has identified genetic abnormalities that drive pre-cancer cells into becoming invasive head and neck cancer. The study found that patients with specific genetic imbalances are less likely to respond to immunotherapy.
The NCI-MATCH cancer clinical trial is expanding with the addition of a new treatment arm, Arm Z1M, which targets mismatch repair deficiency and LAG-3 protein expression. This brings the total number of available treatment arms to 12, addressing 12 unique molecular targets and corresponding drugs that have shown efficacy evidence.
The UK Markey Cancer Center has launched a clinical trial to evaluate the anti-cancer activity of ArtemiLife coffee products in preventing ovarian cancer recurrence. Participants will drink coffee up to four times daily for five months after completing treatment, aiming to delay or eliminate cancer return.
Researchers at Ohio State University Comprehensive Cancer Center identified distinct mutational and molecular changes in four SCLC subtypes, providing new insights into treatment resistance. The findings suggest that subtyping patients before systemic therapy could play a role in drug development and therapy selection.